Inhibition of inflammatory response is critical in the course of RA treatment, and biological agents, such as TNF-α monoclonal antibodies, IL-6 monoclonal antibodies, and JAK pathway inhibitors, have been developed for inflammatory factors and have achieved significant clinical efficacy. Here, TNF is linked to rheumatoid arthritis.